A Phase II Single-Arm Trial of BIBW 2992 in EGFR FISH Positive Non-Small Cell Lung Cancer Patients.
Phase of Trial: Phase II
Latest Information Update: 15 Dec 2014
At a glance
- Drugs Afatinib (Primary)
- Indications Non-small cell lung cancer
- Focus Pharmacogenomic; Therapeutic Use
- Sponsors Boehringer Ingelheim Pharmaceuticals
- 10 Jun 2017 Biomarkers information updated
- 27 Jun 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 27 Jun 2012 Actual patient number (70) added as reported by ClinicalTrials.gov.